



#6

0320

Docket No. 45579 (0001)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT: C. Elling, et al.

U.S.S.N.: 09/752,102

FILED: December 29, 2000

FOR: A METHOD OF IDENTIFYING LIGANDS OF BIOLOGICAL TARGET  
MOLECULES

---

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service in an envelope as First Class Mail addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

July 30, 2001

By: Norah C. Sullivan  
Norah C. Sullivan

---

**INFORMATION DISCLOSURE STATEMENT  
(SUBMISSION AFTER FILING OF AN APPLICATION  
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE)**

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, Applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

**I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION**

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- a. X Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- b.      Each of the patents, publications or other information listed on the attached PTO-1449 was previously cited by or submitted to the USPTO in connection with U.S.S.N.:                     , to which the subject application claims the benefit of the earlier filing date. As such, a copy of each is not included herewith pursuant to 37 C.F.R. § 1.98(d).

III. CONCISE EXPLANATION OF THE RELEVANCE  
(check at least one box)

- a. X Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).
- b.      A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
- English translation for reference(s)             .
  - English abstract for reference(s)     .
  - English translation of search report/ official communication.
  - Copy of PCT/EPO Search Report.
- c.      The following additional information is provided for the Examiner's consideration:
- Copy of EPO Search Report.
  - Copy of PCT Search Report.
  - Copy of Official Communication from the      Patent Office.
  - English translation of search report/ official communication.
  - Copy of             .

**FEES**

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)  
(check one box)

- a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.
- b. ☐ within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.
- c. ☒ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$240.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):  
(check one box)

before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

- a. ☐ No certification; therefore, a fee in the amount of \$240.00 is required by 37 C.F.R. § 1.17(p).
- or
- b. ☐ See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby certifies that

- a. ☐ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- b. ☐ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making

reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

c. \_\_\_\_\_ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VII. FEE PAYMENT (check one)

\_\_\_\_\_ Enclosed please find a check in the amount of \$240.00 for the above-indicated fee.

\_\_\_\_\_ Please charge Deposit Account No. 04-1105 in the amount of \$240.00 for the above-indicated fee.

X  No fee is required.


If the Examiner has any questions concerning the IDS, he/she is requested to contact the undersigned. If it is determined that the IDS has been filed under the wrong rule, the PTO is requested to consider the IDS under the proper rule, with a petition if necessary, and charge the appropriate fee to Deposit Account No. 04-1105.

July 30, 2001

  
\_\_\_\_\_  
John B. Alexander, Ph.D. (Reg. P-48,399)  
Dike, Bronstein, Roberts & Cushman  
Intellectual Property Practice Group  
**EDWARDS & ANGELL, LLP**  
P. O. Box 9169  
Boston, MA 02209

Tel. No. (617) 439-4444

Customer No.: 21874

FORM PTO-1449	ATTY DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT	45579	09/751,202
	APPLICANT(S) C. Elling, et al.	
	FILING DATE 12/29/00	GROUP NO.

**UNITED STATES PATENT DOCUMENTS**

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,147,782	9/15/1992	Brocks, et al	435	7.21	3/11/1988

**FOREIGN PATENT DOCUMENTS**


		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO

**OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)**

	CA	E. Sun, et al., <i>Gene</i> , 137(1):127-132, (1993)
	CB	J. Kuhlmann, <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 37(12):575-583, (1999)
	CC	C. Strader, et al., <i>FASEB Journal</i> , 3:1825-1832, (1989)
	CD	C. Strader, et al., <i>Journal of Biological Chemistry</i> , 266(1):5-8, (1991)
	CE	H. Schambye, <i>Mol Pharm.</i> 47:425-431, (1995)
	CF	B. Holst, et al., <i>Mol Pharm</i> 53: 166-175 (1998)
	CG	H. Dohlman et al., <i>Annual Review Biochemistry</i> , 60:653-88, (1991)
	CH	T. Schwartz, <i>Current Opinion in Biotechnology</i> , 5:434-444, (1994)
	CI	P. Chakrabarti, et al., <i>Protein Engineering</i> , 4(1):57-63 (1990)
	CJ	R. Jernigan, et al. <i>Current Opinion Struct. Biol.</i> 4: 256-263 (1994)
	CK	C. Elling, et al., <i>Fold. Des.</i> 2 (4) S76-S80 (1997)
	CL	C. Elling, et al., <i>Nature</i> , Vol 374: 74-77 (1995)
	CM	C. Elling, et al., <i>Embo J.</i> 15 (22) pp 6213-6219 (1996)
	CN	C. Elling, et al., <i>PNAS</i> 96: 12322-123247, (1999)

**EXAMINER:**

**DATE:**

FORM PTO-1449	ATTY DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT	45579	09/751,202
	APPLICANT(S)	C. Elling, et al.
	FILING DATE	12/29/00
		GROUP NO.

**UNITED STATES PATENT DOCUMENTS**

EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**


		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO

**OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)**

	CO	C. Strader, et al., <i>Annual Reviews, Biochemistry</i> , 1994, 63:101-32
	CP	T. Schwartz, et al., 1995 <i>Curr. Pharm. Des.</i> 1: 325-342 (1995)
	CQ	Joyce M. Baldwin, <i>Embo J.</i> 12 (4): 1693-1703 (1993)
	CR	K. Thirstrup, et al., <i>The Journal of Biological Chemistry</i> , Vol. 271, No. 14, pp 7875-7878 (1996)
	CS	M. Rosenkilde, et al., <i>J. Biol. Chem.</i> 274: (2): 956-961 (1999)
	CT	S. Wilson, <i>British Journal of Pharmacology</i> (1998) 125, 1387-1392
	CU	Joyce M. Baldwin, <i>Current Opinion Cell Biol.</i> 6: 180-190 (1994)
	CV	J. Stadel, et al., <i>TIPS</i> , 18:430-437, (1997)
	CW	R. Reinscheid, et al., <i>Science</i> Vol. 270, pp.792-794, (1995)
	CX	T. Sakurai, et al., <i>Cell</i> , Vol. 92, 573-585, (1998)
	CY	J. Chambers, et al., <i>Nature</i> , 400:261-265, (1999)
	CZ	H. Sarau, et al., <i>Mol Pharma</i> , 56:657-663 (1999)
	CCA	M. Wigler, et al., <i>Cell</i> , Vol. 14, 725-731, (1978)

**EXAMINER:**

**DATE:**

<b>FORM PTO-1449</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>			<b>ATTY DOCKET NO.</b>  45579		<b>SERIAL NO.</b>  09/751,202		
			<b>APPLICANT(S)</b> C. Elling, et al.				
			<b>FILING DATE</b> 12/29/00		<b>GROUP NO.</b>		
<b>UNITED STATES PATENT DOCUMENTS</b>							
<b>EXAM. INITIAL</b>		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>FILING DATE IF APPROPRIATE</b>
<b>FOREIGN PATENT DOCUMENTS</b>							
		<b>DOCUMENT NUMBER</b>	<b>DATE</b>	<b>COUNTRY</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>TRANSLATION YES/NO</b>
<b>OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)</b>							
	CCB	M. Rosenkilde, et al., <i>FEBS Letters</i> , 439:35-40, (1998)					
	CCC	K. Kask, et al., <i>EMBO Journal</i> , Vol. 15, No. 2, pp. 236-244, (1996)					
	CCD	Ho, Steffan, et al., <i>Gene</i> , 77, (1989) 51-59					
	CCE	S. Sheikh, et al., <i>Nature</i> , 383:347-350, (1996)					
	CCF	Herzyk, et al., <i>J. Mol. Biol</i> (1998) 281, 741-754					
	CCG	Unger, et al., <i>Nature</i> , 389:203-206, (1997)					
	CCH	T. Schwartz, <i>TIPS</i> , 17:213-216, (1996)					
	CCI	L. Norregaard, et al., <i>EMBO Journal</i> , Vol. 17, No. 15 pp. 4266-4273, (1998)					
	CCJ	B. Holst, <i>Mol Pharma</i> 58: 263-270, (2000)					
	CCL	M. Dennis, <i>Nature</i> 404:465-470, (2000)					
	CCM	C. Redfern, <i>Nature Biotechnology</i> , 17:165-169, (1999)					
<b>EXAMINER:</b>					<b>DATE:</b>		